---
title: "Chinese Innovative Drugmaker Haisco Inks USD3 Billion R&D Deal With Eli Lilly"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288358921.md"
description: "Chinese drugmaker Haisco Pharmaceutical Group signed a USD3 billion R&D deal with Eli Lilly to jointly develop up to five innovative medicines. Haisco will handle early-stage research using its small-molecule platform, while Eli Lilly secures exclusive commercialization rights outside China. Haisco retains rights in Greater China and receives up to USD87 million upfront plus milestone payments and royalties."
datetime: "2026-06-02T03:30:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288358921.md)
  - [en](https://longbridge.com/en/news/288358921.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288358921.md)
generator: "portal-rs"
---

# Chinese Innovative Drugmaker Haisco Inks USD3 Billion R&D Deal With Eli Lilly

(Yicai) June 2 -- Chinese innovative drug developer Haisco Pharmaceutical Group has signed an agreement worth more than USD3 billion with US pharmaceutical giant Eli Lilly to jointly develop innovative medicines across multiple therapeutic areas.

Haisco will conduct drug discovery and early-stage research and development of up to five innovative drug programs identified by Eli Lilly, leveraging its proprietary small-molecule innovative technology platform, the Chengdu-based company announced yesterday, citing the deal inked on May 29.

Once the innovative drugs are developed, Eli Lilly will own their exclusive commercialization rights for all territories outside China, while Haisco will retain the rights of certain products in the Chinese mainland, Hong Kong, Macao, and Taiwan, according to the agreement.

Haisco will receive upfront and near-term payments of up to USD87 million and no more than USD3 billion in downstream milestone payments. It will also be eligible for single-digit tiered royalties on future product sales.

Haisco develops therapies covering anesthetic analgesia, respiratory diseases, oncology, autoimmune disorders, and chronic illnesses. Its self-developed anesthetic drug Cipepofol Injection became the first innovative intravenous anesthetic made in China to be approved by the US Food and Drug Administration for the US market at the end of last month.

Haisco’s shares \[SHE: 002653\] were trading down 2.4 percent at CNY48.95 (USD7.23) as of 10.30 a.m. in Shenzhen today, after opening up 2 percent.

Editor: Futura Costaglione

### Related Stocks

- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)

## Related News & Research

- [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md)
- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)
- [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md)
- [Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY](https://longbridge.com/en/news/296017075.md)
- [LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs](https://longbridge.com/en/news/295005008.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**